# Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

> **NCT04787991** · PHASE1 · COMPLETED · sponsor: **Cancer Insight, LLC** · enrollment: 45 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Nivolumab (Cohort A)
- **DRUG:** Ipilimumab (Cohort A, B and C)
- **DRUG:** Hydroxychloroquine (HCQ) (Cohort B)
- **DRUG:** Nab-paclitaxel (nP) (Cohort A, B and C)
- **DRUG:** Gemcitabine (gem) (Cohort A, B and C)
- **DRUG:** NG350A (Cohort C)

## Key facts

- **NCT ID:** NCT04787991
- **Lead sponsor:** Cancer Insight, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-09
- **Primary completion:** 2024-11-12
- **Final completion:** 2025-07-31
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04787991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04787991, "Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04787991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*